Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer
J. M. Del Campo,A. Roszak,Mariusz Bidziński,T. E. Ciuleanu,Thomas Högberg,M Z Wojtukiewicz,Andres Poveda,K. Boman,Anneke M. Westermann,C. Lebedinsky +9 more
TLDR
Both every-3-weeks trabectedin regimes were active and reasonably well tolerated in AOC platinum-sensitive patients and deserves to be further evaluated in relapsed AOC.About:
This article is published in Annals of Oncology.The article was published on 2009-11-01 and is currently open access. It has received 62 citations till now. The article focuses on the topics: Trabectedin.read more
Citations
More filters
Journal ArticleDOI
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial
Andres Poveda,Ignace Vergote,Sergei Tjulandin,B. Kong,M. Roy,Stephen Chan,E. Filipczyk-Cisarz,Hans Hagberg,Stan B. Kaye,Nicoletta Colombo,C. Lebedinsky,Trilok V. Parekh,J. Gomez,Youn C. Park,V. Alfaro,Bradley J. Monk +15 more
TL;DR: This hypothesis-generating analysis demonstrates that superior benefits with trabectedin/PLD in terms of PFS and survival in the overall population appear particularly enhanced in patients with partially sensitive disease (PFI 6–12 months).
Journal ArticleDOI
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma
Alessandro Gronchi,Binh Bui,S. Bonvalot,S. Pilotti,Silvia Ferrari,Peter Hohenberger,Raymond J. Hohl,George D. Demetri,A. Le Cesne,Pilar Lardelli,I. Perez,Antonio Nieto,J. C. Tercero,Vicente Alfaro,Elena Tamborini,Jean-Yves Blay +15 more
TL;DR: Trabectedin 1.5 mg/m(2) given as a 24-h i.v. infusion every 3 weeks is a therapeutic option in the neoadjuvant setting of ML, with a safety profile similar to that described in patients with soft tissue sarcoma or other tumor types.
Journal ArticleDOI
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
Axel Le Cesne,Sara Cresta,Robert G. Maki,Jean-Yves Blay,Jaap Verweij,Andres Poveda,Paolo G. Casali,Carme Balaña,Patrick Schöffski,Federica Grosso,Pilar Lardelli,Antonio Nieto,Vicente Alfaro,George D. Demetri +13 more
TL;DR: A phase III randomised trial in first-line is ongoing to compare trabectedin with doxorubicin-based chemotherapy in patients with TRS, showing encouraging disease control in TRS.
Journal ArticleDOI
Targeting apoptosis pathways by natural compounds in cancer: marine compounds as lead structures and chemical tools for cancer therapy.
TL;DR: Natural compounds derived from marine organisms and their synthetic derivates are an important source for new therapeutics for single agent or combined therapy with other chemotherapeutics to support the struggle against cancer.
Journal ArticleDOI
A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials
Axel Le Cesne,A. Yovine,Jean-Yves Blay,Suzette Delaloge,Robert G. Maki,Jean-Louis Misset,Pilar Frontelo,Antonio Nieto,Juhui James Jiao,George D. Demetri +9 more
TL;DR: Single-agent trabectedin treatment was reasonably well tolerated in patients with advanced solid tumors and can be administered for prolonged periods to patients with sustained clinical benefit without cumulative toxicities over time.
References
More filters
Journal ArticleDOI
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
TL;DR: The comparable efficacy, favorable safety profile, and convenient dosing support the role of PLD as a valuable treatment option in patients with epithelial ovarian carcinoma that recurred after or didn't respond to first-line, platinum-based chemotherapy.
Journal ArticleDOI
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
Maurie Markman,R Rothman,T Hakes,Bonnie Reichman,William J. Hoskins,Stephen C. Rubin,Walter B. Jones,Lois Almadrones,J. J. Lewis +8 more
TL;DR: Primary responses to cisplatin/carboplatin-based treatment are common in patients with ovarian cancer who have previously responded to the agents and increase in frequency with greater distance from the initial therapy.
Journal ArticleDOI
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.
Elizabeth Eisenhauer,W.W. ten Bokkel Huinink,Kenneth D. Swenerton,Luca Gianni,James Myles,M.E.L. van der Burg,Ian G. Kerr,Jan B. Vermorken,K Buser,Nicoletta Colombo +9 more
TL;DR: In this article, the dose-response relationship of Taxol in relapsed ovarian cancer and the safety of a short infusion given with pre-medication was investigated in a bifactorial design.
Journal ArticleDOI
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
TL;DR: Long-term follow-up demonstrates that treatment with pegylated liposomal doxorubicin significantly prolongs survival compared with topotecan in patients with recurrent and refractory epithelial ovarian cancer.
Related Papers (5)
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Bradley J. Monk,Thomas J. Herzog,Stanley B. Kaye,Carolyn N. Krasner,Jan B. Vermorken,Franco M. Muggia,Eric Pujade-Lauraine,Alla Lisyanskaya,A. Makhson,Janusz Rolski,Vera Gorbounova,Prafull Ghatage,Mariusz Bidziński,Keng Shen,Hextan Y.S. Ngan,Ignace Vergote,Joo-Hyun Nam,Youn C. Park,Claudia Lebedinsky,Andres Poveda +19 more